Effects of salmeterol, formoterol and placebo on pulmonary function and symptom recovery after histamine provocation in mild asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 710s Year: 2004
Inhaled mannitol improves lung function assessed by forced oscillation in a placebo controlled trial in patients with bronchiectasis Source: Eur Respir J 2004; 24: Suppl. 48, 470s Year: 2004
Double blind, placebo controlled crossover study in COPD patients to assess the acute effect of budesonide/formoterol using HRCT and lung function tests Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011
The impact of a high fine particle fraction inhaled long acting ß2 agonist (Formoterol) on airway function in asthma: evaluation with oxygen enhanced MRI and multiple breath washout. Source: International Congress 2017 – Imaging markers for COPD and asthma Year: 2017
Diagnostic value of determining static versus dynamic lung volumes in the recognition of airways responsiveness to a bronchodilator in asthmatic children Source: Eur Respir J 2001; 18: Suppl. 33, 493s Year: 2001
The improvements of lung function tests after formoterol administration in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 323s Year: 2004
The bronchodilator test in patients with chronic airway obstruction: the responsiveness of lung function parameters Source: International Congress 2018 – Respiratory physiology and measurements Year: 2018
The effects of early intervention with inhaled budesonide on lung function in mild persistent asthma: results from the START study Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003
Assessment of long-term effects of combined extra-fine beclomethasone and formoterol treatment in asthma patients using functional imaging Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010
Effects of low dose inhaled theophylline (ADC4022) co-administered with budesonide on inflammatory markers, lung function, and quality of life in COPD patients Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
Evaluation of the acute bronchodilator effect of beclomethasone/formoterol fixed combination on central and peripheral airway dimensions in asthmatic patients Source: Annual Congress 2009 - Translational research/biomarkers Year: 2009
Improvement of lung function after a 6-week placebo controlled budesonide treatment in symptomatic infants with decreased airways conductance Source: Eur Respir J 2004; 24: Suppl. 48, 157s Year: 2004
Response to bronchodilation with tiotropium plus salbutamol correlates with radiologic morphology of the lung in COPD of the emphysematous phenotype Source: Annual Congress 2010 - Lung imaging Year: 2010
FEV6 : a useful outcome measure of lung function in COPD as assessed in a large clinical study with roflumilast Source: Eur Respir J 2004; 24: Suppl. 48, 342s Year: 2004
Comparison of emphysema in patients with COPD before and after treatment of tiotropium by quantitative assessment by HRCT Source: Eur Respir J 2007; 30: Suppl. 51, 619s Year: 2007
In-vitro emitted dose characteristics of combination budesonide / formoterol tubuhaler using patient inhalation profiles Source: International Congress 2015 – Lung function: waiting to exhale... Year: 2015
Clinical relevance of small airways assessment by lung function tests in asthma Source: International Congress 2018 – Biomarkers and lung function in airway disease Year: 2018
Effects of adding salmeterol to inhaled corticosteroids on lung function and quality of life in patients with mild persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006
Metronome-paced hyperventilation, CT measurements and exercise to investigate dynamic hyperinflation contrasting tiotropium versus indacaterol treatment in moderate COPD patients Source: International Congress 2015 – Unravelling the mechanisms of symptoms and exercise limitationas in disease Year: 2015
Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: A 52 week pooled analysis Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013